Aytu BioPharma (NASDAQ:AYTU) Share Price Passes Below 50 Day Moving Average – Here’s What Happened

Aytu BioPharma Inc. (NASDAQ:AYTU) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.19 and traded as low as $2.09. Aytu BioPharma shares last traded at $2.13, with a volume of 21,280 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AYTU shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Monday, July 6th. Ascendiant Capital Markets lifted their price target on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a report on Thursday, June 11th. Finally, Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $10.75.

Aytu BioPharma Stock Performance

The company has a 50-day simple moving average of $2.18 and a two-hundred day simple moving average of $2.40. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The firm has a market capitalization of $23.08 million, a P/E ratio of -0.47 and a beta of 0.24.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The firm had revenue of $12.41 million during the quarter, compared to analysts’ expectations of $12.05 million. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. As a group, equities analysts forecast that Aytu BioPharma Inc. will post -0.73 EPS for the current year.

Institutional Trading of Aytu BioPharma

A number of hedge funds have recently modified their holdings of AYTU. Persistent Asset Partners Ltd increased its stake in shares of Aytu BioPharma by 27.2% in the 4th quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after acquiring an additional 16,963 shares in the last quarter. Bellevue Asset Management LLC bought a new stake in Aytu BioPharma during the fourth quarter worth about $65,000. Rothschild Wealth LLC purchased a new stake in Aytu BioPharma in the fourth quarter worth about $52,000. XTX Topco Ltd purchased a new stake in Aytu BioPharma in the fourth quarter worth about $67,000. Finally, DRW Securities LLC bought a new position in shares of Aytu BioPharma during the fourth quarter valued at approximately $76,000. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.